Main menu button

Carlsquare Equity Research interview with Biosergen

Equity Research
7 Mar 2024

Carlsquare Equity Research interview with Biosergen
Niklas Elmhammer
Niklas Elmhammer LinkedIn
Senior Equity Analyst
+46 70 898 39 59

Similar News

Equity research Zinzino: Preview Zinzino Q1 2026 - Some moderation of growth
16 Apr 2026
Equity research Zinzino: Preview Zinzino Q1 2026 - Some moderation of growth
Equity Research Zinzino
Equity Research KlaraBo, Q1 2026: Improved focus on property management
15 Apr 2026
Equity Research KlaraBo, Q1 2026: Improved focus on property management
Equity Research KlaraBo
Equity research Svenska Aerogel, Q1 2026: Distribution is expanding, but it is still early commercially
15 Apr 2026
Equity research Svenska Aerogel, Q1 2026: Distribution is expanding, but it is still early commercially
Equity Research Svenska Aerogel
Equity research CDON: Preview Q1 2026 - Continued growth, but initiatives will likely hamper earnings
13 Apr 2026
Equity research CDON: Preview Q1 2026 - Continued growth, but initiatives will likely hamper earnings
Equity Research CDON
Equity research Enrad, Q1 2026: Positive EBITDA in sight, but the real story starts in H2
13 Apr 2026
Equity research Enrad, Q1 2026: Positive EBITDA in sight, but the real story starts in H2
Equity Research Enrad